Larotrectinib news

All news on Larotrectinib (also known as Vitrakvi): plants, production capacities, investments and involved companies.

16 September 2026

Chugai: FoundationOne CDx approved as companion diagnostic for tovorafenib in BRAF‑altered/fusion glioma

Approval allows FoundationOne CDx to detect BRAF V600 alterations and BRAF fusion genes to guide tovorafenib treatment in glioma and expands companion indications to nine cancer types.

Who will be producing Larotrectinib in the future?

Find out with chemXplore Alpha

Learn more